Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H22FNO.ClH |
| Molecular Weight | 299.811 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
InChI
InChIKey=MQHYXXIJLKFQGY-UHFFFAOYSA-N
InChI=1S/C16H22FNO.ClH/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14;/h4-7,13H,2-3,8-12H2,1H3;1H
| Molecular Formula | C16H22FNO |
| Molecular Weight | 263.3504 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
|||
| Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
|||
| Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
43 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
100 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
340 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
206 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
218 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
478 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1490 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
211 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
523 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
570 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140807/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
MELPERONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: extrapyramidal side effects... |
100 mg 4 times / day multiple, oral Highest studied dose Dose: 100 mg, 4 times / day Route: oral Route: multiple Dose: 100 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| extrapyramidal side effects | 4 patients | 100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [IC50 >133 uM] | ||||
| no [IC50 >133 uM] | ||||
| no [IC50 >133 uM] | ||||
| no [IC50 >133 uM] | ||||
Page: 50.0 |
no | |||
Page: 108.0 |
no | |||
Page: 101.0 |
no | |||
Page: 97.0 |
no | |||
Page: 98.0 |
no | |||
| yes [IC50 0.195 uM] | yes (co-administration study) Comment: Melperone decreased dose-adjusted serum venlafaxine concentration by 71.7%. |
|||
Page: 6.0 |
yes [IC50 34.6713 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 94 | 95 |
no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 4.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. | 2010-10 |
|
| Four-digit replantation in a mentally retarded person: a case report. | 2010-09-30 |
|
| Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. | 2010-04-30 |
|
| Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. | 2010-02 |
|
| Acute administration of clozapine and risperidone altered dopamine metabolism more in rat caudate than in nucleus accumbens: a dose-response relationship. | 2009-08-20 |
|
| Antipsychotics and risk of venous thromboembolism: A population-based case-control study. | 2009-08-09 |
|
| Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. | 2009-07 |
|
| Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism. | 2009-04 |
|
| The ABCB1 transporter gene and antidepressant response. | 2009-03-24 |
|
| The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008-12-22 |
|
| [Recurrent dysregulation of body temperature during antipsychotic pharmacotherapy]. | 2008-03 |
|
| Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. | 2006-04 |
|
| Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. | 2006-03-30 |
|
| Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. | 2006-02-28 |
|
| Antipsychotic drugs and QT prolongation. | 2005-09 |
|
| Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. | 2005-02 |
|
| P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. | 2004-12 |
|
| [The case of a 86-years old woman first diagnosed with Huntington's disease]. | 2004-11 |
|
| A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. | 2003-07-01 |
|
| Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2003-03 |
|
| The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. | 2003-01-01 |
|
| Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. | 2003-01 |
|
| Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. | 2002-11-29 |
|
| Melperone in the treatment of neuroleptic-resistant schizophrenia. | 2001-12-31 |
|
| [Pharmacotherapeutical approaches to insomnia patients with cardiac diseases and after heart transplantation]. | 2001-10 |
|
| Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. | 2001-10 |
|
| Clinical management of agitation in the elderly with tiapride. | 2001-01 |
|
| New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. | 1999-06 |
|
| Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents. | 1989-06 |
Patents
Sample Use Guides
The recommended dose of melperone (in form of hydrochloride salt) is 25-75 mg/day. In the case of restless and confused patients the drug is given at a dose of 50-100 mg at the beginning of the treatment. The dose can be increased up to 200 mg if necessary. In severe disorders of confusion and confusion with aggression and hallucinatory conditions, the daily dose can be increased to up to 400 mg melperone HCl.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:57:18 GMT 2025
by
admin
on
Mon Mar 31 17:57:18 GMT 2025
|
| Record UNII |
88G640374K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
289623
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
m7165
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | Merck Index | ||
|
C008522
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
760102
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
SUB14503MIG
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
15386
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
216-599-9
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
88G640374K
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
DTXSID10936649
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
1622-79-3
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY | |||
|
100000092068
Created by
admin on Mon Mar 31 17:57:18 GMT 2025 , Edited by admin on Mon Mar 31 17:57:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |